Read by QxMD icon Read

Japanese Journal of Clinical Oncology

Tetsuo Saito, Ryo Toya, Etsushi Tomitaka, Tomohiko Matsuyama, Satoshi Ninomura, Takahiro Watakabe, Natsuo Oya
Background: We previously demonstrated that patients with painful hematologic tumors were more likely to experience pain response after palliative radiotherapy (RT) than those with painful solid tumors. However, it is unknown whether change in pain interference differs between these two tumor types. In the present study, we carried out a secondary analysis of our previous prospective observational study to investigate this matter. Methods: From patients undergoing palliative RT to treat painful tumors, Brief Pain Inventory data were collected at the start of RT and at the 1-, 2-, and 3- month follow-ups...
September 19, 2018: Japanese Journal of Clinical Oncology
Jeongshim Lee, Hee Ji Han, Byung So Min, Sung Pil Hong, Sang Joon Shin, Hong In Yoon, Soo Jung Park, Woong Sub Koom
Objectives: High-dose pelvic radiotherapy (RT) is known to be associated with chronic radiation proctitis (RP). However, the effects of intermediate radiation doses are unknown. We assessed the incidence of late clinical RP among patients with rectal cancer receiving intermediate-dose postoperative RT, as well as the role of early endoscopic abnormalities in predicting RP development. Methods: We retrospectively reviewed 153 patients with rectal cancer who received postoperative RT at a median dose of 54 Gy between 2005 and 2009 and who underwent endoscopic examination within 12 months thereafter...
September 15, 2018: Japanese Journal of Clinical Oncology
Miyako Tsuchiya, Mariko Masujima, Miki Mori, Miyako Takahashi, Tomoyasu Kato, Shun-Ichi Ikeda, Chikako Shimizu, Takayuki Kinoshita, Sho Shiino, Makiko Suzuki
Objectives: To compare gynaecological and breast cancer patients in their information-seeking behaviours, usefulness of information sources and ongoing care needs after discharge to prevent the onset of lymphoedema. Methods: We conducted a consecutive cross-sectional survey in an oncology hospital. Adult patients with stage I, II or III gynaecological or breast cancer who had undergone lymph node dissection and had not been diagnosed with lymphoedema were eligible for inclusion...
September 6, 2018: Japanese Journal of Clinical Oncology
Shiro Hinotsu, Mikio Namiki, Seiichiro Ozono, Hideyuki Akaza
The National Comprehensive Cancer Network, an NPO organization comprised of university hospitals and cancer centers in the US. The publication of clinical practice guidelines on the treatment, diagnosis, prevention and screening is one of important activities. Background factors of prostate cancer patients, such as the prevalence, age at the diagnosis and mortality are markedly different between Western countries and Asia. Thus, various factors should be taken into consideration at the treatment choice for individual patients...
September 4, 2018: Japanese Journal of Clinical Oncology
Ko Okabe, Tetsuya Shindo, Takeshi Maehana, Naotaka Nishiyama, Kohei Hashimoto, Naoki Itoh, Atsushi Takahashi, Keisuke Taguchi, Hitoshi Tachiki, Toshiaki Tanaka, Naoya Masumori
Objectives: The aim of this study was to evaluate the efficacy of neoadjuvant gemcitabine and cisplatin (GC) therapy for muscle-invasive bladder cancer (MIBC). Methods: We retrospectively evaluated patients who underwent neoadjuvant GC therapy followed by radical cystectomy from April 2009 through December 2015 in the Sapporo Medical University Urologic Consortium. The efficacy of neoadjuvant chemotherapy (NAC) was assessed based on the pathological T0 (pT0) rate in radical cystectomy specimens, and the recurrence-free survival, cause-specific survival and overall survival (OS) rates...
August 28, 2018: Japanese Journal of Clinical Oncology
Yusuke Yoshioka, Takeshi Katsuda, Takahiro Ochiya
Over the past several years, considerable focus has been placed on the need for 'biomarkers'. However, traditional biomarkers, such as CEA or CA19-9, for gastrointestinal cancer do not provide sufficient sensitivity and specificity for diagnosing cancer. Moreover, these biomarkers cannot provide information regarding the individual variability of patients. Recently, extracellular vesicles (EVs) and extracellular microRNA (miRNA) have shown potential in cancer diagnosis because tumor cells have been shown to release EVs and miRNAs, which mirror their cellular origin, into circulation...
August 28, 2018: Japanese Journal of Clinical Oncology
Kojiro Ishinaga, Misato Higa, Miho Yasuda, Miki Kuwana, Chisato Nishiwaki, Masahiro Sunaga, Hitoshi Okamura
Background: Patients receiving chemotherapy experience anorexia and food aversion in their daily lives, and one of the causes is the smell of food. However, it is not clear why the aversion to these smells occurs. This study aimed to determine the emotional responses of patients when they sniff representative food odors during chemotherapy and to investigate factors influencing smell-induced food aversion. Methods: The subjects were 26 patients with lung cancer undergoing chemotherapy with carboplatin...
August 28, 2018: Japanese Journal of Clinical Oncology
Shintaro Yanazume, Noriko Karakida, Ryutaro Higashi, Mika Fukuda, Shinichi Togami, Masaki Kamio, Shunichiro Ota, Hiroaki Kobayashi
Background: The prognostic impact of tumor bleeding requiring intervention and the correlation with anemia on the survival outcome of cervical cancer radiotherapy is unclear. Methods: One hundred and ninety-six patients requiring hemostatic intervention between January 2006 and March 2014 were retrospectively investigated. The correlation between anemia and bleeding during radiotherapy, the prognostic impact of genital bleeding during radiotherapy and the influence of blood transfusion were estimated...
August 25, 2018: Japanese Journal of Clinical Oncology
Masanori Okamoto, Munehisa Kito, Yasuo Yoshimura, Kaoru Aoki, Shuichiro Suzuki, Atsushi Tanaka, Akira Takazawa, Kazushige Yoshida, Hiroyuki Kato
Objective: The purpose of this study is to clarify the status quo of management and clinical outcome of treatments for oldest-old (≥80 years) patients with high-grade soft tissue sarcomas in Japan. Method: The present study was conducted using data from the Soft Tissue Tumor Registry in Japan. There were 956 oldest-old patients with soft tissue sarcoma who were registered from 2006 to 2012. Among them, cases with incomplete data, low-grade soft tissue sarcoma and those who underwent treatment at other institutions were excluded from analysis...
August 22, 2018: Japanese Journal of Clinical Oncology
Fan Dong, Liqi Xu, Xiaoqiong Peng, Tianyuan Xu, Yifan Shen, Fengbin Gao, Xianjin Wang, Xiaohua Zhang, Shanwen Chen, Minguang Zhang, Shan Zhong, Qiang Ding
Objective: To evaluate the prognostic value of lymph node (LN) involvement for patients with chromophobe renal cell carcinoma (chRCC) and ascertain the minimum number of LNs that need to be pathologically examined to reliably diagnose a patient with node negative chRCC. Methods: From 2004 to 2014, non-metastatic chRCC patients receiving radical nephrectomy together with lymphadenectomy were identified from the Surveillance, Epidemiology and End Results (SEER) database...
August 18, 2018: Japanese Journal of Clinical Oncology
Jeongshim Lee, Minkyung Lee, Woong Sub Koom, Hun Jung Kim, Woo Chul Kim
Objective: The prognostic value of metabolic parameters using 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has not been established for early non-small cell lung cancer (NSCLC). Accordingly, the authors investigated the prognostic value of metabolic parameters in terms of failure patterns in patients with early NSCLC who underwent stereotactic body radiation therapy (SBRT). Methods: Data from 35 patients with Stage I NSCLC who underwent SBRT using CyberKnife and received pretreatment FDG PET/CT between 2008 and 2016 were retrospectively reviewed...
August 15, 2018: Japanese Journal of Clinical Oncology
Hironobu Hashimoto, Masakazu Abe, Takako Yanai, Takuhiro Yamaguchi, Sadamoto Zenda, Yosuke Uchitomi, Haruhiko Fukuda, Mikio Mori, Satoru Iwasa, Noboru Yamamoto, Yuichiro Ohe
The Guidelines of the Japan Society of Clinical Oncology recommend standard triple antiemetic therapy with aprepitant, a 5-hydroxytryptamine type 3 receptor antagonist and dexamethasone for patients receiving highly emetogenic chemotherapy. Recently, a Phase III study demonstrated the significance of adding of olanzapine (10 mg) to standard triple antiemetic therapy. Olanzapine is associated with somnolence, and we have previously conducted a randomized Phase II study to evaluate the efficacy and safety of 10 mg and 5 mg olanzapine...
August 14, 2018: Japanese Journal of Clinical Oncology
Yuko Sato, Mitsunori Miyashita, Kazuki Sato, Kenji Fujimori, Koichi Benjamin Ishikawa, Hiromasa Horiguchi, Kiyohide Fushimi, Chikashi Ishioka
Background: End-of-life (EOL) cancer care in Japanese acute care hospitals has not been well described. Methods: We aimed to assess the aggressiveness of EOL care and examine common treatments administered to cancer patients using a health administrative database. Subjects are adult cancer patients who died at acute care hospitals between April 2011 and March 2014. Data from the Japanese Diagnosis Procedure Combination database were analysed to measure the aggressiveness of care (chemotherapy, intensive care unit [ICU] admission and cardiopulmonary resuscitation [CPR]) and describe procedures and prescriptions administered in the last 14 and 30 days of life, disaggregated by hospital case volume: high, intermediate and low volumes...
August 13, 2018: Japanese Journal of Clinical Oncology
Takayuki Oishi, Kazuki Sato, Tatsuya Morita, Jennifer W Mack, Hideki Shimodaira, Masanobu Takahashi, Shin Takahashi, Akira Inoue, Yasuko Murakawa, Masanori Kawahara, Chikashi Ishioka, Mitsunori Miyashita
Background: Although reports have described the perceptions of curability among patients with unresectable/recurrent cancer and the quality of death and dying, the association between patients' perceptions and physicians' disclosures of incurability remained unexplored. This survey aimed to evaluate the association between patients' perceptions of curability and physicians' disclosures of incurability. Methods: In this cross-sectional, multicenter, observational study in Japan, we asked outpatients with unresectable/recurrent solid cancers about their perceptions of incurability...
August 9, 2018: Japanese Journal of Clinical Oncology
N Michaan, S Y Park, Y J Won, M C Lim
Objective: To discuss possible causes of disparities in incidence and mortality rates of ovarian cancer, uterine cancer and cervical cancer between two diverse populations from east and west Asia. Methods: Incidence and mortality data from 1999 to 2013 were extracted from Korean and Israeli cancer registries. Age-standardized rates and annual percent changes were calculated. Trends were analyzed using Joinpoint analysis and discussed with respect to risk factor exposure...
August 3, 2018: Japanese Journal of Clinical Oncology
Yujiao Li, Xiaomin Ou, Chaosu Hu
Backgrounds: With the aim to validate the applicability of the eighth T classifications of AJCC/UICC staging system for nasopharyngeal carcinoma patients. Materials and methods: We compare the seventh and eighth T classifications of the UICC/AJCC staging system in 382 newly diagnosed nasopharyngeal carcinoma patients without cervical lymph node metastasis who were staged with magnetic resonance imaging and treated by intensity-modulated radiotherapy. Univariate analysis was performed using the log-rank test and multivariate analyses with the Cox proportional hazards model were used to evaluate the prognostic values between adjacent stage categories...
August 3, 2018: Japanese Journal of Clinical Oncology
Megumi Hori, Eiko Saito
No abstract text is available yet for this article.
September 1, 2018: Japanese Journal of Clinical Oncology
Toshio Takagi, Kazuhiko Yoshida, Hirohito Kobayashi, Tsunenori Kondo, Junpei Iizuka, Masayoshi Okumi, Hideki Ishida, Hironori Fukuda, Hiroki Ishihara, Kazunari Tanabe
We investigated the efficacy of nivolumab treatment in patients with metastatic renal cell carcinoma who discontinued nivolumab treatment due to reasons other than disease progression. Of the 34 patients, 3 patients discontinued nivolumab therapy due to adverse events and were subsequently observed without additional treatment. The first patient discontinued nivolumab after 14 cycles of treatment due to type 1 diabetes mellitus and has maintained partial remission for 8 months. The second patient discontinued nivolumab after 11 cycles of treatment due to interstitial pneumonitis, and durable response was confirmed for 5 months...
September 1, 2018: Japanese Journal of Clinical Oncology
Kazushige Wakuda, Haruki Kobayashi, Shota Omori, Kazuhisa Nakashima, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Masahiro Endo, Takashi Nakajima, Toshiaki Takahashi
Background: The treatment efficacy of second-line chemotherapy in poor-risk patients with refractory-relapsed small-cell lung cancer is unclear. Methods: We defined refractory relapse as treatment-free interval <90 days and poor-risk as Eastern Cooperative Oncology Group Performance Status ≥2. We retrospectively examined the medical record data of patients who were treated at our hospital between September 2002 and December 2014. Results: Twenty-three poor-risk patients with refractory-relapsed small-cell lung cancer were treated in our hospital...
September 1, 2018: Japanese Journal of Clinical Oncology
Kiyoshi Okazuka, Tadao Ishida
Therapeutic strategies for multiple myeloma have dramatically changed in the last two decades, especially after the introduction of proteasome inhibitors. The first-in-class proteasome inhibitor, bortezomib, was approved by the US Food and Drug Administration in 2003. Since then, it has been a backbone therapy for not only relapsed or refractory myeloma patients but also newly diagnosed multiple myeloma patients. Second-generation proteasome inhibitors, such as carfilzomib and ixazomib, have been approved, and three proteasome inhibitors were incorporated into several regimens with other cytotoxic agents, such as alkylating agents, immunomodulatory drugs and monoclonal antibodies...
September 1, 2018: Japanese Journal of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"